Sarepta Broadens Beyond Elevidys With siRNA Progress And FDA Milestones

• Sarepta Therapeutics (NasdaqGS:SRPT) is progressing its small interfering RNA (siRNA) candidates SRP-1001 and SRP-1003, with early data viewed as encouraging.
• The company is seeking to transition AMONDYS 45 and VYONDYS from accelerated to traditional FDA approvals through recent regulatory submissions.
• These updates come as Sarepta refines its commercial focus beyond gene therapy Elevidys, which continues to face regulatory and commercial complexity.

Sarepta Therapeutics focuses on rare neuromuscular diseases, and for many investors the story has long centered on Elevidys, its gene therapy for Duchenne muscular dystrophy. The fresh attention on siRNA candidates SRP-1001 and SRP-1003, along with efforts to convert AMONDYS 45 and VYONDYS to traditional approvals, gives you more pieces to consider when assessing how the business is evolving.

For investors, the key questions now extend beyond a single therapy to how this broader pipeline and regulatory progress might influence future revenue stability and portfolio risk. The following sections break down what has changed, why it matters for NasdaqGS:SRPT, and which metrics and milestones are likely to shape sentiment from here.

Stay updated on the most important news stories for Sarepta Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Sarepta Therapeutics.

📰 Beyond the headline: 3 risks and 2 things going right for Sarepta Therapeutics that every investor should see.

For you as an investor, this update is less about a single product and more about how Sarepta is trying to balance its portfolio. Elevidys remains central, but the early SRP-1001 and SRP-1003 data, plus the push to move AMONDYS 45 and VYONDYS to traditional approvals, point to a company trying to build more recurring, label-based revenue alongside high-intensity one time gene therapies. That matters because Elevidys has brought regulatory questions and quarter to quarter variability, while the exon-skipping and siRNA franchises may offer a different risk and cash flow profile. At the same time, the siRNA programs are still early and carry execution risk, and Elevidys is operating in a competitive rare-disease field that also includes players like BioMarin, Pfizer and Roche. Given Sarepta has only recently moved from a quarterly loss to a profit, with Q1 2026 net income of US$330.96m on US$730.8m revenue, your focus is likely to be on how repeatable that performance is if Elevidys trends stay mixed and the newer assets take time to scale.

How This Fits Into The Sarepta Therapeutics Narrative

• The push into siRNA therapies and label conversions for AMONDYS 45 and VYONDYS lines up with the narrative that sees future growth coming from a broader RNA and gene therapy portfolio rather than Elevidys alone.
• Ongoing regulatory scrutiny and operational complexity around Elevidys, including safety related updates, still echo the narrative risk that gene therapy uptake could be slower or more volatile than hoped.
• The specific early readouts from SRP-1001 and SRP-1003, plus the timing of AMONDYS 45 and VYONDYS filings, are fresh details that may not yet be fully reflected in the existing community assumptions.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Sarepta Therapeutics to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Earnings are currently expected by analysts to decline on average over the next few years, which can limit how much value the market is willing to ascribe to newer programs.
• ⚠️ The stock has shown a volatile share price in recent months, and Elevidys continues to face regulatory and commercial questions that could affect sentiment quickly.
• 🎁 Sarepta has recently moved from a quarterly net loss to a net income of US$330.96m, and has been described as trading well below one modeled estimate of fair value.
• 🎁 The company is progressing multiple RNA targeted therapies alongside Elevidys, giving investors exposure to several rare-disease programs rather than a single product outcome.

What To Watch Going Forward

From here, you will want to track upcoming clinical readouts for SRP-1001 and SRP-1003, any FDA decisions on converting AMONDYS 45 and VYONDYS to traditional approvals, and signals on Elevidys use in real-world practice. Quarterly updates on revenue mix between gene therapy and RNA products, plus any changes to guidance, will help you judge how durable the recent profitability is. It is also worth watching how regulators and courts handle ongoing safety and patent matters, since they can influence both execution risk and required spending. Together, those pieces will shape whether Sarepta looks more like a concentrated Elevidys story or a more balanced rare-disease platform.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Sarepta Therapeutics, head to the community page for Sarepta Therapeutics to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com